Welcome to our dedicated page for Natera news (Ticker: NTRA), a resource for investors and traders seeking the latest updates and insights on Natera stock.
Natera, Inc. develops and commercializes cell-free DNA and genetic testing for oncology, women’s health and organ health. Company updates commonly cover financial results, revenue trends, laboratory operations and publications supporting tests such as Signatera, Prospera, Panorama and Horizon.
Recurring news also includes oncology molecular residual disease applications, clinical evidence presented at medical meetings, transplant rejection surveillance data, collaborations using Natera assays in drug trials, and patent or litigation developments tied to its MRD technology. The company reports through CLIA-certified and CAP-accredited laboratory operations and through Foresight Diagnostics, its subsidiary.
Natera, Inc. (NASDAQ: NTRA) has completed full enrollment for the RenaCARE study, assessing the utility of its Renasight genetic testing panel for chronic kidney disease (CKD) patients. The study, involving over 1,700 patients across 30+ sites, aims to demonstrate how genetic testing impacts patient care in CKD. The completion of enrollment followed significant interim data analysis. A publication detailing the findings is expected in early 2023, following previous research showing that 10% of CKD cases have a genetic basis.
Natera, Inc. (NASDAQ: NTRA) announced a pre-submission to the FDA for its Panorama® non-invasive prenatal test (NIPT) at the Canaccord Genuity 42nd Annual Growth Conference. This pre-submission, filed in June 2022, addresses fetal chromosomal aneuploidies and 22q11.2 deletion syndrome. The company cited its proactive collaboration with the FDA, supported by results from the SNP-based Microdeletion and Aneuploidy Registry Trial (SMART), the largest NIPT study with over 20,000 patients. Panorama screens for severe genetic disorders as early as nine weeks into pregnancy.
Natera, Inc. (NASDAQ: NTRA) reported Q2 2022 revenues of $198.2 million, a 39.6% increase from Q2 2021. Product revenues also rose by 39.3%. Test processing surged to 499,900, up 33.0% year-over-year. The company raised 2022 revenue guidance to $805 million - $825 million. Notable achievements include securing Medicare coverage for Signatera in muscle-invasive bladder cancer and appointing a new CMO for Oncology. However, net loss reached $145.2 million or ($1.50) per share, compared to ($1.32) in 2021.
Natera, Inc. (NASDAQ: NTRA) will release its second quarter results for 2022 on August 4, 2022, after market close. A conference call will follow at 1:30 p.m. PT (4:30 p.m. ET) to discuss financial results and business outlook. Natera specializes in cell-free DNA testing in oncology, women's health, and organ health, operating ISO-certified laboratories in Texas and California. Investors can register for the call to obtain dial-in details and a unique PIN.
Natera, Inc. (NASDAQ: NTRA) announced that the Federal Circuit Court of Appeals has upheld the invalidation of three CareDx patents, affirming a prior 2021 ruling. This decision is seen as a significant legal victory for Natera, reinforcing its position in the genetic testing market, particularly in cfDNA testing for transplant patients. Chief legal officer Daniel Rabinowitz expressed satisfaction with the court's rejection of CareDx's claims, emphasizing Natera's commitment to innovation and service in the transplant community.
Natera, Inc. (NASDAQ: NTRA) announced that its Signatera molecular residual disease (MRD) test has received coverage from CMS for patients with muscle invasive bladder cancer (MIBC), effective April 19, 2022. This marks the first coverage expansion under the local coverage determination (LCD) for MRD testing in solid tumors. The decision is based on evidence from published studies showing significant benefits of the test in predicting treatment responses and detecting recurrences, thereby improving patient care and decision-making in oncology.
Natera, Inc. (NASDAQ: NTRA) has joined UnitedHealthcare's Preferred Laboratory Network (PLN), effective July 1, 2022. This network includes labs that meet high standards for access, cost, data, quality, and service. Natera's participation aims to enhance patient outcomes and optimize healthcare costs for UnitedHealthcare's members. The company has conducted over 3 million cell-free DNA tests globally, supporting critical healthcare decisions in oncology, women's health, and organ health. Natera is committed to integrating personalized genetic testing into standard care.
Natera, Inc. (NASDAQ: NTRA) announced a breakthrough in kidney transplant rejection assessment with its Prospera™ test, validated in the Transplantation journal. The new two-threshold algorithm significantly improves performance by combining donor-derived cfDNA fraction and quantity, achieving AUCs of 0.88 and 0.91 for detecting active rejection. The 'Trifecta' study analyzed 367 biopsy-matched samples, marking the largest cohort in this research area. This advancement underscores the effectiveness of molecular methods over traditional biopsies, promising more reliable diagnostics for transplant recipients.
Natera, Inc. (NASDAQ: NTRA) presented significant data on its Prospera™ and Renasight™ tests during the American Transplant Congress (ATC) 2022, showcasing advancements in detecting kidney transplant rejection. The two-threshold algorithm for the Prospera test demonstrated superior performance over the traditional dd-cfDNA percentage, with AUC scores of 0.88 and 0.82 against molecular and histological biopsy assessments, respectively. Natera's commitment to innovation is underscored by the presentation of 14 sessions and 13 peer-reviewed papers over the past year, enhancing its leadership in transplant diagnostics.
Natera, Inc. (NASDAQ: NTRA) announced new clinical data on its Signatera molecular residual disease (MRD) test, to be presented at the 2022 ASCO Annual Meeting from June 3-7, 2022. Key findings include 82% detection of ctDNA pre-treatment in non-small cell lung cancer (NSCLC) patients and 100% detection of relapses prior to imaging. In breast cancer, Signatera demonstrated an 88% detection rate for recurrence. Additionally, ctDNA dynamics predicted outcomes in renal cell carcinoma. These insights highlight Signatera's effectiveness in monitoring cancer treatment and detecting recurring disease.